Effect of OIP5-AS1 on Clinicopathological Characteristics and Prognosis of Cancer Patients: a Meta-Analysis

Recent research indicates that OPA-interacting protein 5 antisense RNA 1 (OIP5-AS1) played an essential role in a wide variety of carcinomas. Thus, we sought to evaluate the role of OIP5-AS1 in cancer patients to comprehend the OIP5-AS1 function in cancer better. The studies were collected using network databases, while the odds ratios (ORs) or hazard ratios (HRs) were extracted from included articles. The OIP5-AS1 role in cancer was further analyzed by pooled analysis. A total of 18 studies involved 1181 patients who were diagnosed with 13 different types of cancer. Combined analysis showed that OIP5-AS1 overexpressing patients had a poorer overall survival (OS) rate than those with lower expression (pooled HR = 1.541, 95% confidence interval (CI) = 1.351-1.757, P < 0.001). Interestingly, elevated OIP5-AS1 expression was found to be linked to cancer's unfavorable clinicopathological aspects, including larger tumor size (pooled OR = 0.274, 95% CI = 0.164-0.455, P < 0.001), advanced TNM stage (pooled OR = 0.301, 95% CI = 0.211-0.427, P < 0.001), and lymph node metastasis (pooled OR = 0.407, 95% CI = 0.234-0.706, P = 0.001). OIP5-AS1 was suggested to be a promising prognostic biomarker and a candidate target for cancer therapeutic strategies.